106516-24-9
106516-24-9
Chemical Structure
Sertindole
Synonym(s): Lu 23-174
- CAS No.: 106516-24-9
- Formula:C24H26ClFN4O
- Molecular Weight:440.94
IUPAC Name: 1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl)piperidin-1-yl)ethyl)imidazolidin-2-one
InChIKey: GZKLJWGUPQBVJQ-UHFFFAOYSA-N
SMILES: FC1=CC=C(N2C3=CC=C(Cl)C=C3C(C4CCN(CCN5CCNC5=O)CC4)=C2)C=C1
Biological Activity: Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and αl-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sertindole | 99.92% | Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and αl-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sertindole (Standard) | ≥98% | Sertindole (Standard) is the analytical standard of Sertindole. This product is intended for research and analytical applications. Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and αl-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sertindole-d4 | 98.64% | Sertindole-d4 is the deuterium labeled Sertindole. Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. David Murdoch, et al. Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55. [Content Brief]
- [2]. Wei Zhang, et al. Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep. 2018 Oct 25;8(1):15753. [Content Brief]
- [3]. Mario F Juruena, et al. Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis. 2011 May 17;3:75-85. [Content Brief]
